Phase II Trial of Maintenance Pembrolizumab Following Weekly Paclitaxel for Platinum-resistant Ovarian, Fallopian Tube or Peritoneal Cancer
Phase of Trial: Phase II
Latest Information Update: 01 Oct 2019
Price : $35 *
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Acronyms PROMPT
- 26 Sep 2019 Planned End Date changed from 1 Jan 2022 to 16 Nov 2020.
- 26 Sep 2019 Planned primary completion date changed from 1 Jul 2020 to 16 Nov 2020.
- 26 Sep 2019 Status changed from not yet recruiting to recruiting.